QQQ   311.37 (-0.11%)
AAPL   156.95 (+4.06%)
MSFT   263.18 (-0.54%)
META   192.44 (+1.94%)
GOOGL   106.87 (-0.81%)
AMZN   108.10 (-4.26%)
TSLA   197.24 (+4.76%)
NVDA   215.86 (-0.57%)
NIO   11.68 (-2.34%)
BABA   106.93 (-2.56%)
AMD   87.86 (-0.51%)
T   19.87 (-2.02%)
F   13.41 (-6.35%)
MU   63.61 (+0.70%)
CGC   3.06 (-2.55%)
GE   82.98 (-1.14%)
DIS   112.36 (-0.75%)
AMC   6.68 (+9.87%)
PFE   44.24 (-0.23%)
PYPL   87.57 (+0.70%)
NFLX   377.87 (+2.99%)
QQQ   311.37 (-0.11%)
AAPL   156.95 (+4.06%)
MSFT   263.18 (-0.54%)
META   192.44 (+1.94%)
GOOGL   106.87 (-0.81%)
AMZN   108.10 (-4.26%)
TSLA   197.24 (+4.76%)
NVDA   215.86 (-0.57%)
NIO   11.68 (-2.34%)
BABA   106.93 (-2.56%)
AMD   87.86 (-0.51%)
T   19.87 (-2.02%)
F   13.41 (-6.35%)
MU   63.61 (+0.70%)
CGC   3.06 (-2.55%)
GE   82.98 (-1.14%)
DIS   112.36 (-0.75%)
AMC   6.68 (+9.87%)
PFE   44.24 (-0.23%)
PYPL   87.57 (+0.70%)
NFLX   377.87 (+2.99%)
QQQ   311.37 (-0.11%)
AAPL   156.95 (+4.06%)
MSFT   263.18 (-0.54%)
META   192.44 (+1.94%)
GOOGL   106.87 (-0.81%)
AMZN   108.10 (-4.26%)
TSLA   197.24 (+4.76%)
NVDA   215.86 (-0.57%)
NIO   11.68 (-2.34%)
BABA   106.93 (-2.56%)
AMD   87.86 (-0.51%)
T   19.87 (-2.02%)
F   13.41 (-6.35%)
MU   63.61 (+0.70%)
CGC   3.06 (-2.55%)
GE   82.98 (-1.14%)
DIS   112.36 (-0.75%)
AMC   6.68 (+9.87%)
PFE   44.24 (-0.23%)
PYPL   87.57 (+0.70%)
NFLX   377.87 (+2.99%)
QQQ   311.37 (-0.11%)
AAPL   156.95 (+4.06%)
MSFT   263.18 (-0.54%)
META   192.44 (+1.94%)
GOOGL   106.87 (-0.81%)
AMZN   108.10 (-4.26%)
TSLA   197.24 (+4.76%)
NVDA   215.86 (-0.57%)
NIO   11.68 (-2.34%)
BABA   106.93 (-2.56%)
AMD   87.86 (-0.51%)
T   19.87 (-2.02%)
F   13.41 (-6.35%)
MU   63.61 (+0.70%)
CGC   3.06 (-2.55%)
GE   82.98 (-1.14%)
DIS   112.36 (-0.75%)
AMC   6.68 (+9.87%)
PFE   44.24 (-0.23%)
PYPL   87.57 (+0.70%)
NFLX   377.87 (+2.99%)
NASDAQ:UTHR

United Therapeutics - UTHR Stock Forecast, Price & News

$254.67
-4.81 (-1.85%)
(As of 02/3/2023 11:33 AM ET)
Add
Compare
Today's Range
$254.65
$262.70
50-Day Range
$258.71
$280.43
52-Week Range
$158.38
$283.09
Volume
88,435 shs
Average Volume
338,532 shs
Market Capitalization
$11.61 billion
P/E Ratio
17.32
Dividend Yield
N/A
Price Target
$283.64

United Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.58 Rating Score
Upside/​Downside
8.1% Upside
$283.64 Price Target
Short Interest
Healthy
2.93% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.00
Upright™ Environmental Score
News Sentiment
0.13mentions of United Therapeutics in the last 14 days
Based on 12 Articles This Week
Insider Trading
Selling Shares
$64.75 M Sold Last Quarter
Proj. Earnings Growth
13.03%
From $16.58 to $18.74 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.25 out of 5 stars

Medical Sector

287th out of 1,029 stocks

Pharmaceutical Preparations Industry

135th out of 501 stocks

UTHR stock logo

About United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corp. operates as a biotechnology company engaged in the development and commercialization of products for patients with chronic and life-threatening diseases. The firm markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma. It is involved in the development of novel pharmaceutical therapies and technologies that expand the availability of transplantable organs. The company was founded by Martine A. Rothblatt on June 26, 1996, and is headquartered in Silver Spring, MD.

Receive UTHR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for United Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

UTHR Stock News Headlines

Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
Apple, Amazon, and Walmart are Investing in Solar Energy
The global market for solar energy is expected to be worth an astronomical $1 trillion by the end of 2028, with increasing adoption of solar by commercial, non-profit, and public entities. Even Fortune 500 companies such as Apple, Amazon, and Walmart are investing in solar to help save money over the long term. So it's little wonder solar is also becoming one of the fastest growing sectors in the U.S. stock market.
10 Best Healthcare Stocks For Recession
Analyst Ratings for United Therapeutics
Durham drugmaker names new CEO at pivotal juncture
6 Analysts Have This to Say About United Therapeutics
See More Headlines
Receive UTHR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for United Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

UTHR Company Calendar

Last Earnings
11/03/2021
Today
2/03/2023
Next Earnings (Estimated)
2/23/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:UTHR
CUSIP
91307C10
Employees
965
Year Founded
1996

Price Target and Rating

Average Stock Price Forecast
$283.64
High Stock Price Forecast
$375.00
Low Stock Price Forecast
$203.00
Forecasted Upside/Downside
+11.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.58
Research Coverage
12 Analysts

Profitability

Net Income
$475.80 million
Pretax Margin
49.05%

Debt

Sales & Book Value

Annual Sales
$1.69 billion
Cash Flow
$11.44 per share
Book Value
$87.90 per share

Miscellaneous

Free Float
39,925,000
Market Cap
$11.61 billion
Optionable
Optionable
Beta
0.63

Social Links


Key Executives

  • Martine A. RothblattMartine A. Rothblatt
    Chairman & Chief Executive Officer
  • Michael Ian Benkowitz
    President & Chief Operating Officer
  • James Christopher Edgemond
    Treasurer, Chief Financial & Accounting Officer
  • Paul A. MahonPaul A. Mahon
    Secretary, Executive VP & General Counsel
  • Dewey Steadman
    Head-Investor Relations













UTHR Stock - Frequently Asked Questions

Should I buy or sell United Therapeutics stock right now?

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for United Therapeutics in the last twelve months. There are currently 2 sell ratings, 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" UTHR shares.
View UTHR analyst ratings
or view top-rated stocks.

What is United Therapeutics' stock price forecast for 2023?

12 Wall Street research analysts have issued twelve-month target prices for United Therapeutics' shares. Their UTHR share price forecasts range from $203.00 to $375.00. On average, they predict the company's share price to reach $283.64 in the next twelve months. This suggests a possible upside of 9.3% from the stock's current price.
View analysts price targets for UTHR
or view top-rated stocks among Wall Street analysts.

How have UTHR shares performed in 2023?

United Therapeutics' stock was trading at $278.09 at the beginning of 2023. Since then, UTHR stock has decreased by 6.7% and is now trading at $259.48.
View the best growth stocks for 2023 here
.

When is United Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our UTHR earnings forecast
.

How were United Therapeutics' earnings last quarter?

United Therapeutics Co. (NASDAQ:UTHR) announced its quarterly earnings data on Wednesday, November, 3rd. The biotechnology company reported $3.42 EPS for the quarter, beating analysts' consensus estimates of $3.37 by $0.05. The biotechnology company earned $444.70 million during the quarter, compared to analysts' expectations of $421.45 million. United Therapeutics had a trailing twelve-month return on equity of 16.63% and a net margin of 38.03%. The company's revenue was up 17.0% on a year-over-year basis. During the same period in the prior year, the firm posted $3.84 earnings per share.

What is Martine A. Rothblatt's approval rating as United Therapeutics' CEO?

64 employees have rated United Therapeutics Chief Executive Officer Martine A. Rothblatt on Glassdoor.com. Martine A. Rothblatt has an approval rating of 88% among the company's employees.

What other stocks do shareholders of United Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other United Therapeutics investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), General Electric (GE), Johnson & Johnson (JNJ), Skyworks Solutions (SWKS), Allergan (AGN) and Pfizer (PFE).

What is United Therapeutics' stock symbol?

United Therapeutics trades on the NASDAQ under the ticker symbol "UTHR."

Who are United Therapeutics' major shareholders?

United Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Assenagon Asset Management S.A. (1.32%), Wedge Capital Management L L P NC (0.31%), Allspring Global Investments Holdings LLC (0.27%), Tobam (0.24%), New York State Common Retirement Fund (0.20%) and New York State Teachers Retirement System (0.13%). Insiders that own company stock include Christopher Causey, Christopher Patusky, Judy D Olian, Louis W Sullivan, Martine A Rothblatt, Nilda Mesa, Paul A Mahon, Paul A Mahon, Raymond Dwek, Richard Giltner and Tommy G Thompson.
View institutional ownership trends
.

How do I buy shares of United Therapeutics?

Shares of UTHR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is United Therapeutics' stock price today?

One share of UTHR stock can currently be purchased for approximately $259.48.

How much money does United Therapeutics make?

United Therapeutics (NASDAQ:UTHR) has a market capitalization of $11.83 billion and generates $1.69 billion in revenue each year. The biotechnology company earns $475.80 million in net income (profit) each year or $14.70 on an earnings per share basis.

How many employees does United Therapeutics have?

The company employs 965 workers across the globe.

How can I contact United Therapeutics?

United Therapeutics' mailing address is 1040 SPRING ST, SILVER SPRING MD, 20910. The official website for the company is www.unither.com. The biotechnology company can be reached via phone at (301) 608-9292, via email at ir@unither.com, or via fax at 301-608-9291.

This page (NASDAQ:UTHR) was last updated on 2/3/2023 by MarketBeat.com Staff